Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles: 2022-2025

Historic Amortizatization of Intangibles for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $459,000.

  • Corvus Pharmaceuticals' Amortizatization of Intangibles fell 12.40% to $459,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 29.24%. This contributed to the annual value of $1.1 million for FY2024, which is 27.63% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Amortizatization of Intangibles of $459,000 as of Q3 2025, which was up 37.43% from $334,000 recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Amortizatization of Intangibles high stood at $524,000 for Q3 2024, and its period low was -$83,000 during Q3 2022.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $258,000 (2023), whereas its average is $283,545.
  • In the last 5 years, Corvus Pharmaceuticals' Amortizatization of Intangibles skyrocketed by 545.00% in 2023 and then crashed by 42.80% in 2024.
  • Corvus Pharmaceuticals' Amortizatization of Intangibles (Quarterly) stood at $158,000 in 2022, then decreased by 19.62% to $127,000 in 2023, then spiked by 90.55% to $242,000 in 2024, then decreased by 12.40% to $459,000 in 2025.
  • Its last three reported values are $459,000 in Q3 2025, $334,000 for Q2 2025, and $291,000 during Q1 2025.